Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:author |
Jean-Frederic Colombel
|
| gptkbp:clinicalTrialPhase |
NCT01235689
|
| gptkbp:conditionStudied |
gptkb:Crohn's_disease
|
| gptkbp:controls |
conventional clinical management
|
| gptkbp:country |
multinational
|
| gptkbp:endDate |
2016
|
| gptkbp:foundIn |
Tight control management led to higher rates of mucosal healing than conventional management.
|
| gptkbp:fullName |
Efficacy and Safety of Adalimumab in Patients With Crohn's Disease: The CALM Study
|
| https://www.w3.org/2000/01/rdf-schema#label |
CALM trial
|
| gptkbp:interventionGroup |
tight control (biomarker-based) management
|
| gptkbp:participants |
244
|
| gptkbp:publicationYear |
2018
|
| gptkbp:publishedIn |
gptkb:The_Lancet
|
| gptkbp:result |
mucosal healing
|
| gptkbp:sponsor |
gptkb:AbbVie
|
| gptkbp:startYear |
2011
|
| gptkbp:studiedDrug |
gptkb:adalimumab
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:UCART19
|
| gptkbp:bfsLayer |
8
|